Allspring Global Investments Holdings LLC Boosts Holdings in Natera, Inc. $NTRA

Allspring Global Investments Holdings LLC boosted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 2.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 463,477 shares of the medical research company’s stock after purchasing an additional 8,979 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Natera were worth $94,183,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Reflection Asset Management bought a new stake in shares of Natera in the fourth quarter worth approximately $29,000. Palladiem LLC bought a new position in Natera during the fourth quarter valued at approximately $31,000. Bank of Jackson Hole Trust boosted its holdings in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in Natera in the 4th quarter worth approximately $39,000. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $271.39 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The stock’s 50 day simple moving average is $233.97 and its two-hundred day simple moving average is $220.41. The company has a market cap of $38.87 billion, a price-to-earnings ratio of -166.50 and a beta of 1.51.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45. Following the transaction, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 178,872 shares of company stock worth $39,627,696. Insiders own 5.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTRA. BTIG Research set a $275.00 target price on shares of Natera and gave the company a “buy” rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Canaccord Genuity Group increased their target price on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.